Piramal Group Executive and Leadership Team

Sai Ponugoti, the Chief Executive Officer at Piramal Group, directs the overarching strategic vision for the conglomerate. Overseeing the integration of pharmaceuticals, financial services, and real estate operations, the Chief Executive Officer ensures alignment with long-term growth objectives. This leadership role involves managing complex market dynamics across international territories to maintain competitive advantages. By optimizing resource allocation, Sai Ponugoti drives operational efficiency throughout the entire organization. The Chief Executive Officer collaborates with the Board to refine business models, particularly regarding the adoption of artificial intelligence platforms. Through rigorous oversight of retail and wholesale lending verticals, Ponugoti secures the financial health of the enterprise. Ultimately, the Chief Executive Officer fosters a culture of innovation, ensuring that the conglomerate remains at the forefront of industry advancements while delivering consistent value to shareholders and clients within the global marketplace.

Vivek Valsaraj, the Chief Financial Officer, Piramal Pharma Limited at Piramal Group, directs the fiscal strategy and financial reporting for the pharmaceutical division. Overseeing capital allocation and budgetary discipline, the Chief Financial Officer, Piramal Pharma Limited ensures that the company maintains a robust balance sheet to support ongoing research and development. This leadership role involves managing investor relations and ensuring compliance with international financial standards. By monitoring market trends in the pharmaceutical sector, Vivek Valsaraj drives profitability and cost-efficiency. The Chief Financial Officer, Piramal Pharma Limited collaborates with the executive team to evaluate investment opportunities and risk management protocols. Through the oversight of financial operations, Valsaraj supports the long-term sustainability of the business. Ultimately, the Chief Financial Officer, Piramal Pharma Limited provides the fiscal foundation required for the conglomerate to pursue aggressive growth strategies and maintain leadership in the global healthcare market.

Jatin Lal, the President, Mergers & Acquisitions at Piramal Group, directs the identification and execution of strategic partnerships and corporate acquisitions. Overseeing the evaluation of potential targets, the President, Mergers & Acquisitions ensures that all transactions align with the long-term growth trajectory of the conglomerate. This leadership role involves conducting rigorous due diligence and negotiating complex deal structures across the pharmaceutical and financial service sectors. By identifying synergies that enhance the existing AI-driven platforms, Jatin Lal drives inorganic growth and market expansion. The President, Mergers & Acquisitions collaborates with the C-suite to integrate acquired entities into the broader corporate ecosystem. Through the management of the acquisition pipeline, Lal strengthens the competitive position of the company. Ultimately, the President, Mergers & Acquisitions secures the future of the organization by strategically expanding the footprint and capabilities of the business through targeted investments and high-value corporate alliances.

Arvind Iyer, the Chief Marketing Officer at Piramal Group, architects the brand identity and market positioning for the diverse business portfolio. Overseeing global outreach initiatives, the Chief Marketing Officer ensures that messaging resonates across pharmaceutical and financial service sectors. This leadership role involves crafting data-driven campaigns that highlight the technological advancements within the company, specifically the AI-driven platforms. By analyzing consumer behavior in retail lending, Arvind Iyer drives engagement and expands market reach. The Chief Marketing Officer collaborates with regional heads to tailor communication strategies for varied industry verticals. Through the implementation of digital marketing frameworks, Iyer enhances brand visibility and customer acquisition metrics. Ultimately, the Chief Marketing Officer strengthens the market presence of the conglomerate, ensuring that the brand remains synonymous with innovation and reliability in the eyes of global partners and retail clients alike.

Viral Gandhi, the Chief Technology Officer, Piramal Pharma Piramal Group & Piramal Foundation at Piramal Group, directs the digital transformation and technological infrastructure across the organization. Overseeing the development of AI-driven platforms, the Chief Technology Officer, Piramal Pharma Piramal Group & Piramal Foundation ensures that data analytics support decision-making in pharmaceutical and financial operations. This leadership role involves architecting scalable systems that facilitate retail and wholesale lending efficiency. By integrating advanced software solutions, Viral Gandhi drives innovation within the Piramal Foundation and the broader conglomerate. The Chief Technology Officer, Piramal Pharma Piramal Group & Piramal Foundation collaborates with cross-functional teams to secure digital assets and optimize operational workflows. Through the deployment of cutting-edge technology, Gandhi enhances the agility of the business model. Ultimately, the Chief Technology Officer, Piramal Pharma Piramal Group & Piramal Foundation maintains the technological edge necessary to compete in rapidly evolving global markets.